Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2022PRNewsWire • 07/05/22
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia AreataPRNewsWire • 06/14/22
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47Business Wire • 06/13/22
Data from Incyte's Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual MeetingBusiness Wire • 05/26/22
CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA)PRNewsWire • 05/20/22
FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19Market Watch • 05/11/22
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19PRNewsWire • 05/11/22
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host DiseaseBusiness Wire • 05/05/22
Incyte's (INCY) CEO Hervé Hoppenot on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/03/22
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 05/03/22
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in JapanBusiness Wire • 04/28/22